Bicycle therapeutics reports recent business progress and third quarter 2024 financial results

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported recent business progress and financial results for the third quarter ended september 30, 2024. “in the third quarter, we continued to make significant advancements across our business and pipeline. at esmo, we reported updated data for our clinical-.
BCYC Ratings Summary
BCYC Quant Ranking